Maestroni Umberto, Ziveri Marcello, Azzolini Nicola, Dinale Francesco, Ziglioli Francesco, Campaniello Giovanna, Frattini Antonio, Ferretti Stefania
Unit of Urology, Surgical Departement, University Hospital of Parma, Parma, Italy.
Acta Biomed. 2008 Dec;79(3):211-6.
High-Intensity Focused Ultrasound (HIFU) represents an alternative choice in mini-invasive treatment of prostate cancer. The technology of the device used to perform the treatment allows to exactly destroy a pre-selected area and to save all the tissues around it. We report our experience on the effectiveness and complications of this tecnique.
From May 2006 to April 2007, 25 patients with prostate cancer were treated through Ablatherm (EDAP France) in spinal anesthesia. In the first six patients HIFU and TUR-P (Trans-Urethral Resection of Prostate) were performed in the same session and a suprapubic catheter was placed. In the other 14 patients HIFU was afterwards performed. In these patients a trans-urethral catheter was placed. All patients were divided into three groups: low risk (17 patients), intermediate risk (6 patients) and high risk (2 patients). The follow-up consisted in PSA evaluation after 1, 3, 6, 9, 12 months and in transrectal biopsy after six months. Complications related to the treatment, and symptomatological and sexual life tests were evaluated before and after the treatment.
HIFU overall success rate was 84% (biochemical relapses in only 4 patients out of 25). Success rate was represented as follows: 94.2% in the low risk group, 83.4% in the intermediate risk group and 0% in the high risk group. No complications occurred during the treatment nor in the immediately post-operative time.
We demonstrated that HIFU represents a useful alternative choice in mini-invasive therapy of prostate cancer. Particularly, results are remarkable in localized (low-intermediate risk) and low morbility prostate cancer. The role of this procedure in high risk patients needs to be further evaluated. Transrectal HIFU represents a mini-invasive therapeutic option that makes the treatment of prostate cancer possible in 84% of cases. Our results agree with the literature data and demonstrate that the success of the procedure depends on the correct indication of treatment and is strictly related to progression risk parameters.
高强度聚焦超声(HIFU)是前列腺癌微创治疗的一种替代选择。用于实施该治疗的设备技术能够精确破坏预先选定的区域,并保留其周围的所有组织。我们报告了我们在这项技术的有效性和并发症方面的经验。
2006年5月至2007年4月,25例前列腺癌患者在脊髓麻醉下通过Ablatherm(法国EDAP公司)进行治疗。前6例患者在同一手术中同时进行了HIFU和经尿道前列腺切除术(TUR-P),并放置了耻骨上导管。另外14例患者随后进行了HIFU治疗。在这些患者中放置了经尿道导管。所有患者分为三组:低风险组(17例患者)、中风险组(6例患者)和高风险组(2例患者)。随访包括在1、3、6、9、12个月后进行前列腺特异性抗原(PSA)评估,以及在6个月后进行经直肠活检。评估治疗相关并发症以及治疗前后的症状和性生活测试。
HIFU的总体成功率为84%(25例患者中仅有4例出现生化复发)。成功率如下:低风险组为94.2%,中风险组为83.4%,高风险组为0%。治疗期间及术后即刻均未发生并发症。
我们证明HIFU是前列腺癌微创治疗的一种有用的替代选择。特别是,在局限性(低-中风险)和低发病率的前列腺癌中结果显著。该手术在高风险患者中的作用需要进一步评估。经直肠HIFU是一种微创治疗选择,在84%的病例中使前列腺癌治疗成为可能。我们的结果与文献数据一致,并表明该手术的成功取决于正确的治疗指征,且与进展风险参数密切相关。